An Observational Study of Natural History of Cardiovascular Diseases
NCT ID: NCT02077023
Last Updated: 2019-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
456 participants
OBSERVATIONAL
2014-02-28
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)
NCT01947361
Association of Long-term Conditions With Survival Following Heart Attack in England and Wales
NCT03037255
Etiology and Prevalence of Peripheral Arterial Disease
NCT00005142
Atherosclerosis in Familial Hypercholesterolemia
NCT02489253
Epidemiology of APO- and Lipoproteins in Elderly Women
NCT00005223
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cardiovascular Disease Outcomes Strategy published by Department of Health calls for improving outcomes for people with or at risk of cardiovascular disease by reducing premature mortality rates for CVD by improving prevention, diagnosis and treatment, bringing all services up to the standards of the best. To prevent disease and improve health, it is essential to understand why diseases arise, and conversely why, in many cases, they do not. To do this, it is necessary to study the distribution of natural history of disease in populations and to identify the agents responsible; effective strategies can then be planned. Epidemiology involves the study of populations rather than the direct study of individuals which enhances the practice of medicine by increasing the understanding of how diseases arise and how they might be managed both in the individual and in societies as a whole.
Stroke is one of the top three causes of death in England and a leading cause of adult disability. Approximately 110,000 strokes and a further 20,000 Transient Ischaemic Attacks ('mini strokes') occur in England every year. There are at least 300,000 people in England living with moderate to severe disabilities as a result of stroke. Stroke costs about £7 billion a year.
Most strokes are caused by occlusive arterial disease (obstruction in the vessels providing oxygen rich blood), around 15% are due to atrial fibrillation (AF) which is irregular heart rhythm, and a further 15% or more are associated with carotid stenosis. Many could be avoided if people with AF and Carotid artery stenosis were identified and treated appropriately with antithrombotic, anti-hypertensive and lipid-lowering drugs as well as encouraging them to stop smoking. Some younger patients with tight carotid stenosis, who are well treated medically, can avoid future stroke by appropriate carotid intervention.
The effects of known risk factors can vary enormously from one population to another, and there is still substantial uncertainty as to how important these are in different settings and as to how their importance is changing with time. By understanding the medical, social and ethical factors that affect community health, solutions to public health problems could be developed.
Having access to a large dataset for a range of cardiovascular screening tests provided by Life Line Screening, enable us to reliably study the distribution of natural history of stroke in asymptomatic British and Irish populations and to assess risk factors responsible. We will identify a large cohort of people with asymptomatic Carotid Artery Stenosis (CAS) and AF, drawn from those attending Life Line Screening appointments in the UK to conduct a prospective study to assess the number of cardiovascular events in the cohort and compare it with a group of participants without CAS and AF.
The study consists of an observational, prospective study of the prevalence of and risk factors for AF, CAS and stroke amongst 5,200 people who voluntarily attended cardiovascular screening appointments provided by Life Line Screening. Participants completed a detailed questionnaire and provided information on: prior disease; current medications (i.e. anti-hypertensive, lipid-lowering and anti-platelet therapies); exercise; alcohol intake; smoking history; relevant family medical history; and physical measurements (including height, weight, waist circumference, blood pressure). They were then tested for the following conditions: AF; CAS (with Duplex scanning); Abdominal Aortic Aneurysm (with aortic ultrasound); Peripheral Vascular Disease (with ankle-brachial pressure index). They were provided with a written report and advised to consult their GP to discuss abnormal results. The company recorded all such anonymised data in a research database.
This cohort will have long-term (up to 5 or more years) follow up via an annual interview and/or health questionnaire to determine the contemporary risk of stroke in each group (asymptomatic CAS and/or AF versus no CAS and/or AF).
As the study is quantitative with clear numerical interpretation, Mann-Whitney test and t-test will be used for the statistical analysis. The median and interquartile range will be used to summarise continuous variables such as age. Data and all appropriate documentation will be stored for a minimum of 10 years after the completion of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Asymptomatic Carotid Artery Disease, AF
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult participants over the age of 20
* Participants who filled in appropriate health questionnaire and signed relevant consent part of their questionnaire
* Cohort observation cases: participants with significant carotid artery disease (\>50% stenosis) detected by duplex ultrasound and/or AF
* Cohort observation controls: Participants without CAS detected by Duplex ultrasound or AF
Exclusion Criteria
* Participants under 20 years old
* Participants who filled in the health questionnaire incompletely
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oxford
OTHER
Clinical Trial Service Unit and Epidemiological Studies Unit
UNKNOWN
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohssen Chabok, MD
Role: PRINCIPAL_INVESTIGATOR
Imperial College London
Mohammed Aslam, PhD
Role: STUDY_DIRECTOR
Imperial College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Imperial College London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13IC0865
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.